Evaluation of initial results of chemoradiotherapy for stage III-IV oral cavity cancer at Can Tho Oncology Hospital
Main Article Content
Abstract
To evaluate the initial results of treating oral cancer with concurrent chemoradiotherapy (CTM), a clinical intervention study without a control group was conducted on 36 patients with oral cavity cancer from June 2024 to June 2025. The average age was 54.22 ± 8.58 years old. Males accounted for 88.9%. Stage III disease accounted for 11.1%, and stage IV for 88.9% (with IVA accounting for 66.7% and IVB for 22.2%). At 3 months post-treatment, 38.9% of patients had a complete response, 8.3% had progression, and 5.6% were stable. The progression-free survival rates at 3 months, 6 months, and 1 year were 100%, 90.8%, and 75%, respectively. The overall survival rates at 3 months, 6 months, and 1 year were 100%, 100%, and 93.1%, respectively. Patients with oral cancer treated with combined chemoradiotherapy experienced prolonged survival in locally advanced stages.
Article Details
Keywords
Oral cavity cancer, concurrent chemoradiotherapy, Can Tho Oncology Hospital
References
1. Chamoli A, Gosavi AS, Shirwadkar UP, et al. Overview of oral cavity squamous cell carcinoma: Risk factors, mechanisms, and diagnostics. Oral Oncology. 2021;121:105451. doi:10.1016/j.oraloncology.2021.105451
2. Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2024;74(3):229-263. doi:10.3322/caac.21834
3. Cancer (IARC) TIA for R. Global Cancer Observatory. Accessed April 17, 2024. https://gco.iarc.fr/
4. Mohamad I, Glaun MD, Prabhash K, et al. Current treatment strategies and risk stratification for oral carcinoma. Am Soc Clin Oncol Educ Book. 2023;(43):e389810. doi:10.1200/EDBK_389810
5. Nguyễn Chấn Hùng, Lâm Đức Hoàng, và cs. Bước đầu đánh giá đáp ứng và độc tính cấp của hoá xạ đồng thời trong ung thư amidan giai đoạn tiến triển tại chỗ tại vùng. Tạp chí Y học thành phố Hồ Chí Minh. 2009;13(6):91-91.
6. Nguyễn Văn Đăng, Nguyễn Thị Thu Nhung, Nguyễn Thị Hằng, và cs. Đánh giá kết quả hóa xạ trị đồng thời sử dụng kỹ thuật VMAT ung thư khoang miệng giai đoạn III-IVA, B tại Bệnh viện K. Tạp chí Y học Việt Nam. 2022;520(1A). doi:10.51298/vmj.v520i1.3743
7. Lydiatt WM, Patel SG, O’Sullivan B, et al. Head and Neck cancers-major changes in the American Joint Committee on cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67(2):122-137. doi:10.3322/caac.21389
8. Phạm Nguyên Tường. Đánh giá kết quả xạ trị điều biến liều các ung thư biểu mô vảy đầu cổ. Tạp chí Y học lâm sàng Bệnh viện Trung ương Huế. 2019;(55):12-17.
9. Bùi Ngọc Vĩnh Lộc, Trần Thị Phương Đan, Đỗ Thị Thảo. Nghiên cứu đặc điểm lâm sàng, mô bệnh học và một số yếu tố liên quan ở bệnh nhân ung thư hốc miệng tại Bệnh viện ung bướu thành phố Cần Thơ năm 2018-2020. Tạp chí Y Dược học Cần Thơ. 2020;(28):1-8.
10. Nguyễn Thị Minh Linh, Nguyễn Trung Hậu. Khảo sát độc tính và đáp ứng ban đầu của hóa xạ đồng thời bằng cisplatin trong điều trị ung thư đầu cổ tại Bệnh viện Ung bướu Tp. Hồ Chí Minh năm 2020. Tạp chí Y học Việt Nam. 2022;519.
11. Stepan KO, Mazul AL, Larson J, et al. Changing epidemiology of oral cavity cancer in the United States. Otolaryngol Head Neck Surg. 2023;168(4):761-768. doi:10.1177/01945998221098011
12. Mishra VK, Gandhi AK, Rastogi M, et al. Retrospective analysis of clinical outcome of 100 inoperable oral cavity carcinoma treated with definitive concurrent chemoradiotherapy with or without induction chemotherapy. Ecancermedicalscience. 2023;17:1630. doi:10. 3332/ecancer.2023.1630
13. Biswas R, Halder A, Ghosh A, et al. A comparative study of treatment outcome in younger and older patients with locally advanced oral cavity and oropharyngeal cancers treated by chemoradiation. South Asian J Cancer. 2019;8(1):47-51. doi:10.4103/sajc.sajc_7_18
14. Mishra VK, Gandhi AK, Rastogi M, et al. Clinical outcome of inoperable locally advanced carcinoma of oral cavity treated with definitive concurrent chemoradiotherapy: a retrospective analysis from tertiary cancer center. International Journal of Radiation Oncology Biology Physics. 2021;111(3, Supplement):e393. doi:10.1016/j.ijrobp.2021.07.1143
15. Hosni A, Chiu K, Huang SH, et al. Non-operative management for oral cavity carcinoma: Definitive radiation therapy as a potential alternative treatment approach. Radiother Oncol. 2021;154:70-75. doi:10.1016/j.radonc.2020.08.013
16. Elbers JBW, Al-Mamgani A, Paping D, et al. Definitive (chemo)radiotherapy is a curative alternative for standard of care in advanced stage squamous cell carcinoma of the oral cavity. Oral Oncol. 2017;75:163-168. doi:10.1016/j.oraloncology.2017.11.006
17. Lacas B, Carmel A, Landais C, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group. Radiotherapy and Oncology. 2021;156:281-293. doi:10.1016/j.radonc.2021.01.013
18. Kiyota N, Tahara M, Fujii H, et al. Phase II/III trial of post-operative chemoradiotherapy comparing 3-weekly cisplatin with weekly cisplatin in high-risk patients with squamous cell carcinoma of head and neck (JCOG1008). J Clin Oncol. 2020;38(15_suppl):6502-6502. doi:10.1200/JCO.2020.38.15_suppl.6502
19. Szturz P, Wouters K, Kiyota N, et al. Weekly low-dose versus three-weekly high-dose cisplatin for concurrent chemoradiation in locoregionally advanced non-nasopharyngeal head and neck cancer: a systematic review and meta-analysis of aggregate data. Oncologist. 2017;22(9):1056-1066. doi:10.1634/theoncolo gist.2017-0015
20. Ghosh S, Rao PB, Kumar PR, et al. Concurrent chemoradiation with weekly cisplatin for the treatment of head and neck cancers: an institutional study on acute toxicity and response to treatment. Asian Pac J Cancer Prev. 2015;16(16):7331-7335. doi:10.7314/apjcp.2015.16.16.7331
21. Mazul AL, Stepan KO, Barrett TF, et al. Duration of radiation therapy is associated with worse survival in head and neck cancer. Oral Oncol. 2020;108:104819. doi:10.1016/j.oraloncology.2020.104819
22. Kawahara D, Nakano H, Saito A, et al. Dose compensation based on biological effectiveness due to interruption time for photon radiation therapy. Br J Radiol. 2020;93(1111):20200125. doi:10.1259/bjr.202 00125
2. Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2024;74(3):229-263. doi:10.3322/caac.21834
3. Cancer (IARC) TIA for R. Global Cancer Observatory. Accessed April 17, 2024. https://gco.iarc.fr/
4. Mohamad I, Glaun MD, Prabhash K, et al. Current treatment strategies and risk stratification for oral carcinoma. Am Soc Clin Oncol Educ Book. 2023;(43):e389810. doi:10.1200/EDBK_389810
5. Nguyễn Chấn Hùng, Lâm Đức Hoàng, và cs. Bước đầu đánh giá đáp ứng và độc tính cấp của hoá xạ đồng thời trong ung thư amidan giai đoạn tiến triển tại chỗ tại vùng. Tạp chí Y học thành phố Hồ Chí Minh. 2009;13(6):91-91.
6. Nguyễn Văn Đăng, Nguyễn Thị Thu Nhung, Nguyễn Thị Hằng, và cs. Đánh giá kết quả hóa xạ trị đồng thời sử dụng kỹ thuật VMAT ung thư khoang miệng giai đoạn III-IVA, B tại Bệnh viện K. Tạp chí Y học Việt Nam. 2022;520(1A). doi:10.51298/vmj.v520i1.3743
7. Lydiatt WM, Patel SG, O’Sullivan B, et al. Head and Neck cancers-major changes in the American Joint Committee on cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67(2):122-137. doi:10.3322/caac.21389
8. Phạm Nguyên Tường. Đánh giá kết quả xạ trị điều biến liều các ung thư biểu mô vảy đầu cổ. Tạp chí Y học lâm sàng Bệnh viện Trung ương Huế. 2019;(55):12-17.
9. Bùi Ngọc Vĩnh Lộc, Trần Thị Phương Đan, Đỗ Thị Thảo. Nghiên cứu đặc điểm lâm sàng, mô bệnh học và một số yếu tố liên quan ở bệnh nhân ung thư hốc miệng tại Bệnh viện ung bướu thành phố Cần Thơ năm 2018-2020. Tạp chí Y Dược học Cần Thơ. 2020;(28):1-8.
10. Nguyễn Thị Minh Linh, Nguyễn Trung Hậu. Khảo sát độc tính và đáp ứng ban đầu của hóa xạ đồng thời bằng cisplatin trong điều trị ung thư đầu cổ tại Bệnh viện Ung bướu Tp. Hồ Chí Minh năm 2020. Tạp chí Y học Việt Nam. 2022;519.
11. Stepan KO, Mazul AL, Larson J, et al. Changing epidemiology of oral cavity cancer in the United States. Otolaryngol Head Neck Surg. 2023;168(4):761-768. doi:10.1177/01945998221098011
12. Mishra VK, Gandhi AK, Rastogi M, et al. Retrospective analysis of clinical outcome of 100 inoperable oral cavity carcinoma treated with definitive concurrent chemoradiotherapy with or without induction chemotherapy. Ecancermedicalscience. 2023;17:1630. doi:10. 3332/ecancer.2023.1630
13. Biswas R, Halder A, Ghosh A, et al. A comparative study of treatment outcome in younger and older patients with locally advanced oral cavity and oropharyngeal cancers treated by chemoradiation. South Asian J Cancer. 2019;8(1):47-51. doi:10.4103/sajc.sajc_7_18
14. Mishra VK, Gandhi AK, Rastogi M, et al. Clinical outcome of inoperable locally advanced carcinoma of oral cavity treated with definitive concurrent chemoradiotherapy: a retrospective analysis from tertiary cancer center. International Journal of Radiation Oncology Biology Physics. 2021;111(3, Supplement):e393. doi:10.1016/j.ijrobp.2021.07.1143
15. Hosni A, Chiu K, Huang SH, et al. Non-operative management for oral cavity carcinoma: Definitive radiation therapy as a potential alternative treatment approach. Radiother Oncol. 2021;154:70-75. doi:10.1016/j.radonc.2020.08.013
16. Elbers JBW, Al-Mamgani A, Paping D, et al. Definitive (chemo)radiotherapy is a curative alternative for standard of care in advanced stage squamous cell carcinoma of the oral cavity. Oral Oncol. 2017;75:163-168. doi:10.1016/j.oraloncology.2017.11.006
17. Lacas B, Carmel A, Landais C, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group. Radiotherapy and Oncology. 2021;156:281-293. doi:10.1016/j.radonc.2021.01.013
18. Kiyota N, Tahara M, Fujii H, et al. Phase II/III trial of post-operative chemoradiotherapy comparing 3-weekly cisplatin with weekly cisplatin in high-risk patients with squamous cell carcinoma of head and neck (JCOG1008). J Clin Oncol. 2020;38(15_suppl):6502-6502. doi:10.1200/JCO.2020.38.15_suppl.6502
19. Szturz P, Wouters K, Kiyota N, et al. Weekly low-dose versus three-weekly high-dose cisplatin for concurrent chemoradiation in locoregionally advanced non-nasopharyngeal head and neck cancer: a systematic review and meta-analysis of aggregate data. Oncologist. 2017;22(9):1056-1066. doi:10.1634/theoncolo gist.2017-0015
20. Ghosh S, Rao PB, Kumar PR, et al. Concurrent chemoradiation with weekly cisplatin for the treatment of head and neck cancers: an institutional study on acute toxicity and response to treatment. Asian Pac J Cancer Prev. 2015;16(16):7331-7335. doi:10.7314/apjcp.2015.16.16.7331
21. Mazul AL, Stepan KO, Barrett TF, et al. Duration of radiation therapy is associated with worse survival in head and neck cancer. Oral Oncol. 2020;108:104819. doi:10.1016/j.oraloncology.2020.104819
22. Kawahara D, Nakano H, Saito A, et al. Dose compensation based on biological effectiveness due to interruption time for photon radiation therapy. Br J Radiol. 2020;93(1111):20200125. doi:10.1259/bjr.202 00125